Petr Husa

Summary

Affiliation: Masaryk University
Country: Czech Republic

Publications

  1. ncbi request reprint Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patients
    P Husa
    Department of Infectious Diseases, University Hospital, Brno, Czech Republic
    Acta Virol 45:7-11. 2001
  2. ncbi request reprint [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics]
    Petr Husa
    Department of Infectious Diseases, Medical Faculty, Masaryk University and Faculty Hospital Brno, Czech Republic
    Klin Mikrobiol Infekc Lek 14:67-73. 2008
  3. ncbi request reprint [Hepatitis C virus infection in sex workers]
    Petr Husa
    Department Infectious Diseases, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic
    Klin Mikrobiol Infekc Lek 13:66-9. 2007
  4. ncbi request reprint [The effect of patient's body weight, gender and baseline viral load on the efficacy of hepatitis C therapy]
    P Husa
    Klinika infekcních chorob Lékaské fakulty MU a FN Brno
    Vnitr Lek 52:590-5. 2006
  5. ncbi request reprint [The meaning of viral kinetics in the beginning of the pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C]
    P Husa
    Klinika infekcních chorob Lékarské fakulty MU a FN Brno
    Vnitr Lek 52:153-9. 2006
  6. ncbi request reprint Hepatitis D
    P Husa
    Department of Infectious Diseases, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic
    Acta Virol 49:219-25. 2005
  7. ncbi request reprint Efficacy and safety of chronic hepatitis C treatment in hemophilic patients
    P Husa
    Department of Infectious Diseases, University Hospital Brno, Czech Republic
    Hepatogastroenterology 52:1541-4. 2005
  8. ncbi request reprint Treatment of chronic hepatitis C in hemophilic patients
    P Husa
    Department of Infectious Diseases, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic
    Acta Virol 48:35-8. 2004
  9. ncbi request reprint Treatment of chronic hepatitis B in 2002
    P Husa
    Department of Infectious Diseases, University Hospital, Masaryk University, Brno, Czech Republic
    Bratisl Lek Listy 104:59-63. 2003
  10. ncbi request reprint Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons
    P Husa
    Department of Infectious Diseases, Teaching Hospital, Jihlavska 20, CZ 639 00 Brno, Czech Republic
    Bratisl Lek Listy 102:248-52. 2001

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patients
    P Husa
    Department of Infectious Diseases, University Hospital, Brno, Czech Republic
    Acta Virol 45:7-11. 2001
    ....
  2. ncbi request reprint [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics]
    Petr Husa
    Department of Infectious Diseases, Medical Faculty, Masaryk University and Faculty Hospital Brno, Czech Republic
    Klin Mikrobiol Infekc Lek 14:67-73. 2008
    ....
  3. ncbi request reprint [Hepatitis C virus infection in sex workers]
    Petr Husa
    Department Infectious Diseases, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic
    Klin Mikrobiol Infekc Lek 13:66-9. 2007
    ..The work assessed the prevalence of hepatitis C virus (HCV) infection in a representative sample of both male and female sex workers with the aim of assessing sexual transmission of HCV infection...
  4. ncbi request reprint [The effect of patient's body weight, gender and baseline viral load on the efficacy of hepatitis C therapy]
    P Husa
    Klinika infekcních chorob Lékaské fakulty MU a FN Brno
    Vnitr Lek 52:590-5. 2006
    ..Today, the standard therapy of patients with chronic HCV (hepatitis C virus) infection is based on combination of pegylated interferon alpha (PEG-IFN) and ribavirin...
  5. ncbi request reprint [The meaning of viral kinetics in the beginning of the pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C]
    P Husa
    Klinika infekcních chorob Lékarské fakulty MU a FN Brno
    Vnitr Lek 52:153-9. 2006
    ..Pegylated interferon alpha (PEG-IFN) and ribavirin combination therapy is the contemporary standard therapy of the patients chronically infected with hepatitis C virus (HCV)...
  6. ncbi request reprint Hepatitis D
    P Husa
    Department of Infectious Diseases, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic
    Acta Virol 49:219-25. 2005
    ..The results of antiviral therapy of hepatitis D patients are not satisfactory. Alpha-interferon (alpha-IFN) in high doses (9-10 MU three times a week for 12 months) is usually recommended...
  7. ncbi request reprint Efficacy and safety of chronic hepatitis C treatment in hemophilic patients
    P Husa
    Department of Infectious Diseases, University Hospital Brno, Czech Republic
    Hepatogastroenterology 52:1541-4. 2005
    ..Chronic hepatitis C infection is very common among hemophiliacs in the developed World...
  8. ncbi request reprint Treatment of chronic hepatitis C in hemophilic patients
    P Husa
    Department of Infectious Diseases, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic
    Acta Virol 48:35-8. 2004
    ..We conclude that the efficacy and tolerability of the treatment of chronic hepatitis C in hemophiliacs did not differ from that of chronic hepatitis C in other patients...
  9. ncbi request reprint Treatment of chronic hepatitis B in 2002
    P Husa
    Department of Infectious Diseases, University Hospital, Masaryk University, Brno, Czech Republic
    Bratisl Lek Listy 104:59-63. 2003
    ..These approaches are including antisense oligonucleotides, ribozymes, inhibitors blocking virus entry into hepatocytes, and decoy virus or dominant negative mutants...
  10. ncbi request reprint Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons
    P Husa
    Department of Infectious Diseases, Teaching Hospital, Jihlavska 20, CZ 639 00 Brno, Czech Republic
    Bratisl Lek Listy 102:248-52. 2001
    ..We can expect the development more potent antiviral drugs or immune modulators for patients, which are primary resistant to alpha-interferon. (Tab. 3, Ref. 31)..
  11. ncbi request reprint Efficacy of alpha-interferon therapy of chronic hepatitis patients infected with wild type hepatitis B virus and HBEAG-minus mutant
    P Husa
    Department of Infectious Diseases, University Hospital Brno, Czech Republic
    Acta Virol 45:293-7. 2001
    ..Nevertheless, 4 of 7 patients of group B were negative for HBV DNA 12 months after the treatment and HBV DNA was eliminated during the treatment in all patients of group C; however, 3 patients relapsed after the treatment...
  12. doi request reprint Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe
    Petr Husa
    Department of Infectious Diseases, Faculty Hospital and Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic
    Eur J Gastroenterol Hepatol 23:375-81. 2011
    ..To assess the safety and efficacy of 48 weeks of re-treatment with peginterferon α-2a (40 kD) plus ribavirin in previously treated hepatitis C virus (HCV) genotype 1 patients...
  13. ncbi request reprint [RILPIVIRINE -- a novel HIV-1 non-nucleoside reverse transcriptase inhibitor]
    Svatava Snopková
    Department of Infectious Diseases, Medical Faculty of Masaryk University, The University Hospital Brno, Czech Republic
    Klin Mikrobiol Infekc Lek 19:19-22. 2013
    ..Multicentre studies ECHO and THRIVE are also reviewed. Current guidelines for the treatment of HIV/AIDS are mentioned as well as the role of RPV in current therapeutic regimens. ..
  14. ncbi request reprint [Marseille fever imported from Spain]
    Michaela Freibergerová
    Department of Infectious Diseases, University Hospital, Masaryk Universita, Brno, Czech Republic
    Klin Mikrobiol Infekc Lek 10:191-4. 2004
    ..The clinical manifestation, diagnosis and treatment of Marseille fever are discussed in greater detail...
  15. ncbi request reprint Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders
    Eugene R Schiff
    Division of Hepatology, University of Miami, Jackson Medical Towers, 1500 N W 12th Avenue, Suite 1101, Miami, FL 33136, USA
    J Hepatol 38:818-26. 2003
    ..We assessed lamivudine treatment, with or without added interferon, in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had failed interferon therapy previously...
  16. ncbi request reprint A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B
    Seng Gee Lim
    National University Hospital, Singapore
    Arch Intern Med 166:49-56. 2006
    ..Emtricitabine is a nucleoside analogue approved for treatment of human immunodeficiency virus 1 with clinical activity against hepatitis B virus (HBV)...
  17. ncbi request reprint Dual hepatitis B virus and hepatitis C virus infection: To treat or not to treat, and how?
    Petr Husa
    J Gastroenterol Hepatol 20:669-70. 2005